# Anheuser-Busch InBev SA/NV (BUD) — Investment Thesis **Exchange:** NYSE **Coverage as of:** 2026-Q2 **Updated:** 2026-05-28 **Tier:** Free primer (steps 1 & 3 of 19) **Sibling pages:** /stocks/BUD/financials · /stocks/BUD/memo > This page shows the free thesis context (business model + recent catalysts). > The full investment thesis (moat analysis, DCF, scenarios, risk register) is available > via GET /api/v1/research/BUD/memo ($2.00, Bearer token). ## Business Model --- source: coverage-next-full ticker: BUD step: 01 title: Business Model & Overview generated: 2026-05-28 --- ### Step 01 — Business Model & Overview #### Key Findings - BUD is the **world's largest brewer** by volume (~25% global share) [S9] and by revenue ($59.3B FY25 [S2]), with ~500 brands across ~50 countries. - Operates as a **vertically-integrated, asset-heavy global brewer + distributor**: owns barley supply (in part), maltings, breweries, packaging, logistics, and in many EMs the direct-to-retail B2B platform (BEES) [S7]. - Profit pool concentrated in just **three economies — US, Brazil, Mexico** — which together contribute >60% of EBITDA [S7]. This is the central geographic concentration risk and opportunity. - **Three global brands** (Budweiser, Corona, Stella Artois) anchor the premium portfolio; **megabrand set** (~70% of revenue) extends to Michelob Ultra, Modelo Mexico, Brahma, Skol, Beck's, Hoegaarden, Leffe [S7]. - Net positive for the thesis — global scale + diversified profit pool + vertical control + premium-portfolio compounding all genuine moat sources. #### Implications for Thesis and Valuation The business model has three valuation-relevant features: 1. **Operating leverage from premium mix-shift** — premium portfolio +6.3% revenue growth vs flat total volumes [S7]; even modest mix shifts move EBITDA. 2. **Cash generation is structural, not cyclical** — vertically-integrated + countercyclical beer category + low capex requirement (3.5% of revenue) → FCF $11.2B reliable [S4]. 3. **BEES B2B platform** ($50B+ GMV [S7]) is an embedded distribution moat that competitors cannot easily replicate; this is the under-modeled asset in most sell-side decks. #### Objective Map BUD's business model — what they make, how they make money, how they distribute, where the profit pool sits, and what the value-chain layers are. #### Narrative Analysis **What BUD does.** Brews, packages, distributes, and markets beer (and a growing adjacent portfolio of hard seltzer, RTD cocktails, alcohol-free beer, and ready-mixed drinks) across ~50 countries. Output: roughly 580M HL of beer annually [S9]. **Revenue model — by structural layer:** 1. **Megabrand portfolio (~70% of revenue).** The core profit engine: Budweiser, Corona, Stella, Michelob Ultra, Modelo (Mexico/global ex-US — STZ owns US), Brahma, Skol, Beck's, Hoegaarden, Leffe [S7]. Wholesale to distributors and retail; premium-positioned variants carry 2-3x the EBITDA per HL of standard brands. 2. **Regional / local brands (~25% of revenue).** ~500 SKUs covering value tier in specific geographies — Aguila (Colombia), Cass (Korea), Harbin (China), Quilmes (Argentina). Lower margin but volume defenders. 3. **Beyond Beer (~5% of revenue, +23% growth) [S7].** Cutwater Spirits (US RTD cocktails — triple-digit growth), NUTRL hard seltzer, Mike's Hard Lemonade, Brutal Fruit (S Africa), Flying Fish, Babe Wine. Adjacency expansion; high-margin variable-cost adjacencies that share distribution. 4. **Alcohol-free / no-low alc (~3% of revenue, +34% growth) [S7].** Corona Cero, Budweiser Zero, Stella Zero, Beck's Blue. Among fastest-growing sub-segments globally [S10]; ~20% better unit margin than alcoholic counterparts per AB InBev disclosure. 5. **BEES B2B + DTC platform.** Not a separate revenue line — a distribution enabler. ~$50B GMV across 31 markets [S7]; in places like Brazil and Mexico it directly serves >2M small retailers and bars, with last-mile delivery and credit. Direct economic benefit: better mix, less promo waste, real-time demand signal. Hard to value separately but real strategic moat. **How money is made — economics:** - Net revenue per HL: ~$102 globally (FY25 = $59.3B / 580M HL ≈ $102/HL) - EBITDA per HL: ~$36 (= $21.06B / 580M HL ≈ $36/HL) — premium markets >$50/HL, EM value markets <$25/HL [S7] - Premium HL carry +50-80% EBITDA per HL premium vs standard - Capex: ~$3.7B annually = 6.2% of revenue (FY25), down from 10.4% in FY21 [S4] - Working capital: structurally negative ($-9.7B WC FY25 [S3]) — suppliers and distributors finance the business; this is a meaningful float advantage **Value-chain layer map:** | Layer | Owned by BUD? | Notes | |---------------------------|------------------------------------------|---------------------------------------------------------| | Raw materials (barley/hops)| Partial — long-term supply contracts | Some owned malting capacity | | Brewing / packaging | ✓ Fully integrated | ~200+ breweries globally | | Logistics | ✓ in EM; mixed in DM | Owned distribution in Brazil/Mexico; 3-tier in US | | Wholesale | Mixed — own in EM, distributor-led in US| US 3-tier system mandates independent distributors | | Retail / on-trade | Partial (some bars, pubs) | Some on-trade ownership in EU; mostly independent retail| | DTC | ✓ Zé Delivery (BR), Tada (LatAm) | Direct-to-consumer in select EM markets | | B2B platform | ✓ BEES | Cuts out distributor sales reps; direct-to-bar | #### Evidence and Sources - Revenue $59.32B FY25, EBITDA $21.06B [S2][S7] - Volume base ~580M HL (industry estimates triangulated with IWSR + 20-F MD&A) [S9] - Segment mix: Middle Americas 29%, NA 24%, SA 20%, EMEA 16%, APAC 10% [S7] - Premium portfolio ~35% of revenue, +6.3% growth [S7] - Beyond Beer +23%, alcohol-free +34% [S7] - BEES GMV ~$50B [S7] - ~144,000 employees [S7] #### Assumption Register Updates - A03 — Premium portfolio ~35% of revenue (Estimate, Med sensitivity) [S7] - A04 — Volume base ~580M HL (Estimate, Low sensitivity) [S7][S9] - A05 — Megabrand revenue concentration ~70% (Fact, Low sensitivity) [S7] #### Tables and Calculations ##### Revenue mix by segment (FY25) | Segment | Rev share | Approx revenue ($B) | EBITDA share (est) | |----------------------|-----------|----------------------|---------------------| | Middle Americas | 29% | 17.2 | ~32% | | North America | 24% | 14.2 | ~24% | | South America | 20% | 11.9 | ~16% | | EMEA | 16% | 9.5 | ~14% | | Asia Pacific | 10% | 5.9 | ~13% | | Global Export & Hldg | 1% | 0.6 | ~1% | ##### Revenue mix by brand-tier (FY25) | Tier | Rev share | YoY growth | Margin profile | |----------------------------|-----------|-------------|------------------------| | Premium + super-premium | ~35% | +6.3% | High (>$50/HL EBITDA) | | Core / classic megabrands | ~50% | -1% to +1% | Medium ($30-40/HL) | | Value / local brands | ~7-8% | flat | Low ($15-25/HL) | | Beyond Beer | ~5% | +23% | High variable margin | | Alcohol-free / no-low alc | ~3% | +34% | +20% vs alcoholic | ##### Per-unit economics (FY25 estimates) | Metric | Value | |------------------|-----------| | Revenue per HL | ~$102 | | EBITDA per HL | ~$36 | | Capex per HL | ~$6.3 | | FCF per HL | ~$19 | #### Open Questions and Data Gaps - BEES profit contribution not separately disclosed — treated as distribution enabler. Value-as-platform argument is qualitative. - Volume HL estimates triangulated; precise volume is not in standardized IFRS statements. #### Source Index | Tag | Document or URL | Section | Date | Notes | |--------|----------------------------------------------------------------------|---------|-------------|---------------------------------------------------------| | [S2] | StockAnalysis.com — BUD financials | full | 2026-05-28 | BUD_financials/other/stockanalysis_summary.md | | [S3] | StockAnalysis.com — BUD balance sheet | full | 2026-05-28 | BUD_financials/xbrl/xbrl_summary.md | | [S4] | StockAnalysis.com — BUD cash flow | full | 2026-05-28 | BUD_financials/xbrl/xbrl_summary.md | | [S7] | AB InBev FY2025 6-K press release / investor presentation | full | 2026-02-11 | BUD_financials/presentations/investor_presentation_2025.md | | [S9] | IWSR 2025 global beer outlook | full | 2026-05-28 | BUD_financials/industry/market_overview.md | | [S10] | BeverageDaily — alcohol-free growth | full | 2026-05-28 | BUD_financials/industry/market_overview.md | ## Recent Catalysts --- source: coverage-next-full ticker: BUD step: 12 title: Bull / Bear — Catalyst Debate generated: 2026-05-28 --- ### Step 12 — Bull / Bear — Catalyst Debate #### Key Findings - The debate over BUD is now structured as **"recovery + capital return inflection"** (bulls) vs **"structural beer-volume decline + Bud Light brand impairment"** (bears). The variance is meaningful but narrowing — Street is ~75% buy [S12]. - **Recovery thesis dominates near-term Street narrative** following Q1-26 +12% revenue print + the $6B buyback + ND/EBITDA <3x milestone. - **Bear case has not gone away** — Bud Light volumes remain materially below pre-2023 levels (~30% down vs 2022 peak per industry sources [S8]); category volumes still falling. - Catalysts to watch: (1) Q2-26 6-K (Jul/Aug) — confirms US Michelob Ultra share, (2) $6B buyback progress, (3) any segment-level US recovery data. #### Implications for Thesis and Valuation This step is critical input to /complete-coverage Step_15 (scenarios) and the public /stocks page Bull/Bear panels. The decision on this debate determines the entire valuation framing. #### Objective Steelman both the bull and bear cases using the analyst-debate framework adapted for the no-transcripts path. **Methodology note:** since earnings call transcripts are not loaded in /coverage-next-full, this step uses (a) 20-F MD&A, (b) FY25 6-K press release [S7], (c) trade-press synthesis [S8][S13], (d) sell-side consensus reports [S12], and (e) news flow [S10]. #### Narrative Analysis ##### THE BULL CASE — Recovery + Capital Return Inflection **Core argument:** BUD has crossed the ND/EBITDA 3.0x threshold, the worst of the Bud Light disruption is behind, premium portfolio compounds at +6%, and the $6B buyback authorization signals management's conviction in cash-flow runway. The stock should re-rate toward a "post-deleveraging high-FCF compounder" multiple, similar to Coca-Cola / Diageo (15-16x EV/EBITDA vs BUD at 12x). **Key supports:** 1. **Capital return inflection is real and observable.** Buyback FY23 $362M → FY25 $2,301M → $6B new authorization [S14]. Dividend +22% FY24 + 15% FY25. Total shareholder yield approaching 5% at current price. 2. **Underlying business is healthier than the headline.** Organic revenue +3.1% / organic EBITDA +4.5% in FY25 [S7]. 65% of markets growing revenue; 75% growing EBITDA. The "premium portfolio +6.3%" growth is the real compounding engine, not aggregate volume. 3. **US recovery underway.** Michelob Ultra is now the #1 US beer by dollar share in selected weeks [S7]. The Bud Light decline rate is decelerating; the brand is no longer in free-fall. Net US revenue is recovering even as Bud Light specifically remains weak. BUD has demonstrated that its portfolio moat (multiple brands) can withstand single-brand impairment. 4. **Beyond Beer + alcohol-free are real growth engines.** Cutwater triple- digit growth; Corona Cero +34%; alcohol-free category +8% globally; BUD gaining ground vs Heineken's first-mover lead [S7][S10]. These adjacencies are high-margin and increase BUD's category share-of-throat. 5. **BEES B2B platform is structurally undervalued.** ~$50B GMV [S7] running through 31 markets; this is a logistics/data moat that would be worth ~$5-10B as a standalone tech asset. Today it's bundled into "AB InBev distribution" and gets no separate credit. 6. **Multiple expansion case.** BUD at 12x EV/EBITDA vs Heineken 11.5x, KO ~22x, Diageo ~16x. As deleveraging finishes (~FY28), BUD should converge toward the Diageo/KO range, implying ~15x = +25% upside on multiple alone. ##### THE BEAR CASE — Structural Volume Decline + Brand Impairment **Core argument:** Beer is a structurally declining category in mature markets; BUD's Bud Light brand is permanently impaired and may never reach pre-2023 share; premium mix-shift will eventually cap; debt remains massive ($73B gross); the founder block forecloses LBO/breakup optionality. **Key supports:** 1. **Industry volume decline is structural, not cyclical.** Global beer -1% volume in 2025 per IWSR [S9]; mature markets flat-to-declining. Gen Z drinks less; GLP-1s reduce alcohol consumption; cannabis displaces beer in US states. Premium mix-shift can offset for a while but math eventually constrains it: premium share already at 35%, ceiling is probably 45-50%. 2. **Bud Light brand impairment may be permanent.** Some ex-AB Inbev execs have publicly stated Bud Light hasn't recovered [S8]. Bud Light volumes remain ~30% below 2022 peak per industry sources [S8]. The Modelo Especial (now Mich Ultra) US #1 position represents a permanent rebalancing in the brand portfolio, with associated marketing-cost inefficiency. 3. **$61B net debt is still huge.** ND/EBITDA 2.87x is "below 3x" but is still high in absolute terms; interest cost ~$4.5B/yr; sensitivity to rate moves real. The "deleveraging completed" celebration assumes target ~2.0x, but mgmt has explicitly said this is "optimal", not "required" — capital return acceleration could pause if EBITDA growth disappoints. 4. **Founder block forecloses optionality.** Stichting AK extension to 2034 [S11] eliminates the activist + LBO premium that otherwise might be embedded in valuation. The maximum-extraction breakup case (e.g., selling US operations to Constellation; selling Ambev minority to local Brazilian buyers) is structurally impossible. 5. **APAC weakness is uncertain.** China consumer slowdown is real; government stimulus has been incremental; mgmt has not put a recovery timeline on the table. APAC ~10% of revenue but disproportionately profitable in premium positions. 6. **Multiple compression risk.** If volume decline accelerates (especially if Bud Light deteriorates further), BUD could compress toward Molson Coors multiples (7-8x EV/EBITDA), representing ~35-40% downside. ##### Synthesizing the debate The bull case is **more correlated to observable data** (deleveraging milestone, $6B buyback, Q1-26 +12% revenue) and **less reliant on assumptions about category structure**. The bear case is **more reliant on long-tail structural arguments** that may or may not materialize over the forecast horizon. Bud Light brand-recovery is a real uncertainty but is largely priced — BUD trades at a discount to KO/ Diageo despite better deleveraging profile. Consensus: **75% buy / 17% hold / 0% sell** [S12]. Average PT $89.90 vs $82.69 spot = ~9% upside [S12]. The Street is structurally bullish but the debate is alive. The /complete-coverage Step_15 scenarios should weight Bull / Base / Bear roughly **40% / 40% / 20%** to reflect this debate. #### Evidence and Sources - ND/EBITDA 2.87x [S14] - $6B buyback [S14] - Organic revenue +3.1% FY25 / +12% Q1-26 [S7][S2] - Premium +6.3% [S7]; Beyond Beer +23%; alcohol-free +34% [S7] - Bud Light volumes still ~30% down vs 2022 [S8] - Founder block extended to 2034 [S11] - Street ratings 10 buy / 2 hold / 0 sell [S12] - Industry volumes -1% [S9] #### Assumption Register Updates - A32 — Bull case organic rev growth FY26-28 = +3.5 to +4.5% (Estimate, High sens) [S7][S12] - A33 — Bear case organic rev growth FY26-28 = +1.0 to +2.0% (Estimate, High sens) [S9] - A34 — Bull/Base/Bear weighting for Step 15 = 40/40/20 (Judgment, Med sens) [S12] #### Tables and Calculations ##### Bull/Bear scoreboard | Dimension | Bull view | Bear view | |--------------------------|-------------------------------------------------|--------------------------------------------------------| | FY26-28 organic rev | +3.5-4.5% | +1-2% | | FY28 ND/EBITDA | ~2.0x; full mgmt-target | ~2.5x; mgmt walks back target | | US Bud Light | Recovery to ~70% of peak by FY28 | Permanent ~50% of peak; portfolio mix-shift absorbs | | EBITDA margin trajectory | 35.5% → 37.5% | 35.5% → 34% | | Multiple | 14-15x EV/EBITDA | 9-10x EV/EBITDA | | FY28 implied stock price | $115-130 | $55-65 | ##### Catalyst calendar (next 12 months) | Date | Catalyst | Bull/Bear lean | |-----------------|------------------------------------------------------------|----------------| | Q2-26 6-K (Jul/Aug 2026) | H1 results — confirms US recovery + premium trajectory | Bull | | FY26 6-K (Feb 2027) | Full-year confirm; ND/EBITDA progress; FY27 guidance | Either | | Buyback execution pace | $6B authorization progress (announced H2 2025) | Bull | | US 2026 summer selling season | Bud Light + Michelob Ultra share movements | Either | | Q3-26 China APAC reads | China consumer recovery / trough confirmation | Either | | Brazilian tax case progress | Settlement / ruling on disputed tax positions | Either | #### Open Questions and Data Gaps - Without transcripts, can't gauge mgmt tone on FY26 organic growth guidance ranges. - Bud Light SKU-level Circana data not directly accessible to this research. #### Next-Step Dependencies - /complete-coverage Step_13 will use the Bull/Base/Bear inputs for forecast - Step_14 will value the scenarios - Step_15 will produce probability-weighted target with the 40/40/20 weighting - Public /stocks page will surface the 3-bullet Bull and Bear cases below #### Source Index | Tag | Document / URL | Section | Date | Notes | |--------|------------------------------------------------------------|---------|-------------|--------------------------------------------------------| | [S2] | StockAnalysis.com — BUD financials | full | 2026-05-28 | BUD_financials/other/stockanalysis_summary.md | | [S7] | AB InBev FY25 6-K + investor presentation | full | 2026-02-11 | BUD_financials/presentations/investor_presentation_2025.md | | [S8] | The Hill / CNN / Fox Business — Bud Light Mulvaney coverage | full | 2026-05-28 | BUD_financials/sec_filings/20F_FY2023_summary.md | | [S9] | IWSR 2025 global beer outlook | summary | 2026-05-28 | BUD_financials/industry/market_overview.md | | [S10] | BeverageDaily — alcohol-free + premium growth | summary | 2026-05-28 | BUD_financials/industry/market_overview.md | | [S11] | SC 13D/A — Stichting AK shareholder pact to 2034 | full | 2026-03 | BUD_financials/proxy/insider_transactions.md | | [S12] | Yahoo Finance / StockAnalysis — BUD analyst consensus | full | 2026-05-28 | BUD_financials/other/consensus.md | | [S14] | StockTitan — AB InBev FY25 results | full | 2026-02-11 | BUD_financials/sec_filings/20F_FY2025_summary.md | --- #### Bull Case — 3 bullets - **Capital return inflection unlocked.** ND/EBITDA crossed below 3.0x for the first time since the 2016 SABMiller deal (now 2.87x); $6B new buyback program underway + progressive +15% dividend; total shareholder yield ~5% with ~$15B further deleveraging headroom before mgmt's ~2.0x target. - **Premium portfolio compounds while volume is flat.** Premium + super-premium +6.3% revenue growth, Beyond Beer +23%, alcohol-free +34% — mix-shift drives organic EBITDA +4.5% even with global beer volumes -1%; Q1-26 reported revenue inflected to +12.0% confirming the recovery is real. - **US "worst is past" + BEES optionality.** Michelob Ultra captured #1 US beer dollar-share in selected 2025 weeks, demonstrating portfolio moat intact; BEES B2B platform at $50B GMV across 31 markets is a structurally undervalued distribution moat the Street largely ignores. #### Bear Case — 3 bullets - **Bud Light brand may be permanently impaired.** Volumes still ~30% below 2022 peak nearly 3 years post-controversy; Modelo Especial took #1 US beer status in 2023 and never gave it back; some ex-execs publicly state recovery has stalled; if Bud Light deteriorates further, US intangibles ($30-40B carrying value) face impairment risk. - **Structural category decline + GLP-1/wellness headwind.** Global beer volumes -1%/yr structural; mature markets flat-to-declining; premium mix- shift has a ceiling (~45-50% of revenue) before it taps out; Gen Z drinks less, RTD cocktails and cannabis substitute, GLP-1s reduce alcohol consumption — these are durable headwinds the model cannot reverse. - **$73B debt + founder block cap optionality.** Gross debt remains huge with $4.5B/yr interest expense; refinancing rates partially offset; meanwhile the Stichting AK founder voting block extension to 2034 eliminates activist/LBO/ breakup optionality that might otherwise support multiple expansion; the stock has to earn its return via execution alone. ## Full Investment Thesis (Premium) The full research tier adds these thesis-critical dimensions: - Moat Analysis — durable competitive advantages, switching costs, network effects - Investment Thesis — variant perception, what has to be true, why market may be wrong - Bull / Base / Bear Scenarios — probability weights, catalysts, price targets - Risk Register — macro, competitive, execution, regulatory risks with materiality ratings - Management Quality — capital allocation track record, incentive alignment - DCF Valuation — 10-year model with sensitivity matrix **API endpoint:** GET /api/v1/research/BUD/memo ## Navigation - Overview: /stocks/BUD - Financials: /stocks/BUD/financials - Thesis (this page): /stocks/BUD/thesis - Investment Memo: /stocks/BUD/memo - Coverage universe: /stocks